CENTURY II Compares Bioresorbable and Permanent Polymer Drug-Eluting Stents in Multivessel CAD at 5 Years
April 30, 2019—The 5‐year results of the CENTURY II randomized clinical trial were published by Andrés Iñiguez, MD, et al online in Catheterization and Cardiovascular Interventions (CCI).
The investigators assessed the long‐term safety and efficacy of a bioresorbable-polymer sirolimus‐eluting stent (BP‐SES; Ultimaster, Terumo Interventional Systems) in comparison to a benchmark permanent-polymer everolimus‐eluting stent (PP‐EES; Xience, Abbott Vascular) in a prespecified subgroup of 456 patients with multivessel coronary artery disease (MV-CAD) from the 1,119 patients (intention to treat) enrolled in the CENTURY II prospective, randomized, single‐blind, multicenter trial.
As summarized in CCI, the 456 MV-CAD patients were allocated by stratified randomization to treatment with BP‐SES (n = 225) or PP‐EES (n= 231). Baseline patient, lesion, and procedural characteristics were similar between the treatment arms.
The primary endpoint of this study was freedom from target lesion failure (TLF; a composite of cardiac death, target vessel–related myocardial infarction [MI], and clinically indicated target lesion revascularization) at 9 months.
The investigators found that both the BP‐SES and PP‐EES displayed low and comparable rates of TLF at 1 year (5.3% vs 7.8%; P = .29) and 5 years (10.2% vs 13.4%; P = .29), as well as definite or probable stent thrombosis at 1 year (90.4% vs. 1.3%; P = .33) and 5 years (0.9% vs 1.7%; P = .43).
Additionally, results regarding the composite endpoint of cardiac death and MI, as well as the patient‐oriented composite endpoint of any death, MI, and coronary revascularization, were similar.
These results confirm good long‐term safety and efficacy of the studied bioresorbable polymer stent in this high‐risk patient population, concluded the investigators in CCI.